Medostic develops proprietary integrated inpatient clinical decision support software to personalize metabolic treatment of critical care patients with the mission of improving glycemic control, inflammation, nutrition and other indications for use common during the acute phase of illness and injury.
Medostic combines measurements of glucose, lactate and other metabolites of the Body Energy State with proprietary algorithms to prescribe personalized infusion administration of formulations and therapeutics for critical care patients.
Medostic proprietary formulations and therapeutics will be indicated for use for metabolic and nutritional needs including glycemic control and other indications for use of critical care patients and are currently in clinical trials.
Changed Science / Changed Medicine
Based on Lactate Shuttle theory discovered by Medostic cofounder Professor George A. Brooks at UC Berkeley, the role of lactate has at least three main uses in the body: It's a major fuel source, it's the major material to support blood sugar (glucose) level and it's a powerful signal for metabolic adaptation to stress.
Lactate supplementation therapy has been shown in clinical trials to improve outcomes in critical care patients with stress hyperglycemia, inflammation (e.g. traumatic brain injury, acute pancreatitis), nutritional needs and other indications for use that are typical during the acute phase of illness and injury.
Michael A. Horning, Cofounder & CEO
George A. Brooks, Cofounder & COO